Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Study examines link between early-stage Alzheimer's and lower BMI

Studies have shown that people who are overweight in middle age are more likely to develop Alzheimer's disease decades later than people at normal weight, yet researchers have also found that people in the earliest stages of Alzheimer's disease are more likely to have a lower body mass index (BMI). A current study examines this relationship between Alzheimer's disease and BMI.

22 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

Two RegeneRx cardiac-related patents receive notice of allowance in Australia, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.

18 Nov 2011

Modified story memory technique may help cognitive rehabilitation in MS patients

John DeLuca, PhD, Vice President for Research at Kessler Foundation presented findings on the use of a behavioral technique for cognitive rehabilitation in people with multiple sclerosis (MS).

17 Nov 2011

CF Foundation, Genzyme announce new drug research agreement

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

17 Nov 2011

People with prior stroke or diabetes benefit from thrombolytic therapy

People with a history of stroke or diabetes who were given clot-busting drugs to break up blood clots after stroke fared better than those who did not receive the drugs, according to a study published in the November 16, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

17 Nov 2011

EPO-secreting engineered vessels could reverse anemia

Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream.

15 Nov 2011

Kessler Foundation researchers to improve rehabilitation after stroke

Kessler Foundation received a $250,000 stroke research grant from the Wallerstein Foundation for Geriatric Life Improvement. Anna Barrett, MD, director of Stroke Rehabilitation Research at Kessler Foundation, will apply the funds to finding better ways to treat hidden disabilities that often complicate recovery after stroke.

15 Nov 2011

Global demand to join pioneering adult stem cell study to treat ALS

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, today announced that patients from across the globe are demanding to be included in the pioneering clinical study started earlier this year at Jerusalem's Hadassah University Medical Center.

14 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Patients with Parkinson's may have increased risk of leg motor restlessness

People with Parkinson's disease may be more likely to have a movement disorder called leg motor restlessness, but not true restless legs syndrome as previous studies have suggested, according to a study published in the November 9, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

10 Nov 2011

Kessler Foundation neuropsychologists receive National Multiple Sclerosis Society grants

Two neuropsychologists at Kessler Foundation Research Center were awarded more than $100,000 in grants by the National Multiple Sclerosis Society. Nancy Chiaravalloti, PhD, received $63,000 to conduct a pilot study, "Speed of Processing Training for Improving Processing Speed in Persons with MS".

8 Nov 2011

BioScrip third quarter revenue increases 2.9% to $454.0 million

BioScrip, Inc. today announced 2011 third quarter financial results. Revenue for the three months ended September 30, 2011 was $454.0 million and net income was $0.5 million, or $0.01 per diluted share, including $5.0 million in restructuring charges, severance and other employee costs.

8 Nov 2011

FDA grants Fast Track designation to Opexa's Tovaxin for treatment of SPMS

Opexa Therapeutics, Inc., announced today that its lead drug candidate Tovaxin® has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Secondary Progressive Multiple Sclerosis.

8 Nov 2011

A person's stroke risk profile may help identify future cognitive problems

A new study shows a person's stroke risk profile, which includes high blood pressure, smoking, and diabetes, may also be helpful in predicting whether a person will develop memory and thinking problems later in the life.

8 Nov 2011

ISET 2012 to discuss latest advances in chronic cerebrospinal venous insufficiency

Innovators in the field of endovascular therapy will explore the often-contentious topic of chronic cerebrospinal venous insufficiency (CCSVI), which is theorized to be a contributing factor in the development of multiple sclerosis (MS), at the 24th annual International Symposium on Endovascular Therapy.

7 Nov 2011

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB, a leading biopharmaceutical company at the forefront of immunology treatment and research, is proud to sponsor several key sets of Cimzia (certolizumab pegol) data at the American College of Rheumatology's 2011 Annual Scientific Meeting in Chicago, November 5-9.

7 Nov 2011

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed results presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, a major multiple sclerosis conference which was held October 19-22, 2011 in Amsterdam.

5 Nov 2011

Active ingredient in saffron shows promise against MS

Medical researchers at the University of Alberta have discovered that an active ingredient in the Persian spice saffron may be a potential treatment for diseases involving neuroinflammation, such as multiple sclerosis.

5 Nov 2011

Opexa reports net loss of $1.30 million for third quarter 2011

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2011 and provided an overview of recent corporate developments.

5 Nov 2011